167 related articles for article (PubMed ID: 24163512)
21. Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma.
Manohar K; Mittal BR; Raja S; Bhattacharya A; Malhotra P; Varma S
Leuk Lymphoma; 2013 Apr; 54(4):714-9. PubMed ID: 22870929
[TBL] [Abstract][Full Text] [Related]
22. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma.
Zanoni L; Mattana F; Calabrò D; Paccagnella A; Broccoli A; Nanni C; Fanti S
Eur J Radiol; 2021 Aug; 141():109793. PubMed ID: 34148014
[TBL] [Abstract][Full Text] [Related]
23. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
24. Italian Multicenter Study on Accuracy of
Cistaro A; Cassalia L; Ferrara C; Quartuccio N; Evangelista L; Bianchi M; Fagioli F; Bisi G; Baldari S; Zanella A; Pillon M; Zucchetta P; Burei M; Sala A; Guerra L; Guglielmo P; Burnelli R; Panareo S; Scalorbi F; Rambaldi I; Piccardo A; Garaventa A; Familiari D; Fornito MC; Lopci E; Mascarin M; Altini C; Ferrari C; Perillo T; Santoro N; Borsatti E; Rubini G
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e267-e273. PubMed ID: 29739722
[TBL] [Abstract][Full Text] [Related]
25. Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma.
Yang DH; Jung SH; Ahn JS; Kim YK; Min JJ; Bom HS; Lee JJ; Kim HJ
Chonnam Med J; 2015 Dec; 51(3):109-14. PubMed ID: 26730361
[TBL] [Abstract][Full Text] [Related]
26. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
27. Kikuchi-Fujimoto disease mimicking malignant lymphoma with 2-[(18)F]fluoro-2-deoxy-D-glucose PET/CT in children.
Kim JE; Lee EK; Lee JM; Bae SH; Choi KH; Lee YH; Hah JO; Choi JH; Kong EJ; Cho IH
Korean J Pediatr; 2014 May; 57(5):226-31. PubMed ID: 25045365
[TBL] [Abstract][Full Text] [Related]
28. Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
Strobel K; Schaefer NG; Renner C; Veit-Haibach P; Husarik D; Koma AY; Hany TF
Ann Oncol; 2007 Apr; 18(4):658-64. PubMed ID: 17308330
[TBL] [Abstract][Full Text] [Related]
29. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
Macapinlac HA
Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
[TBL] [Abstract][Full Text] [Related]
30. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
[TBL] [Abstract][Full Text] [Related]
31. Role of PET in lymphoma.
Gallamini A; Borra A
Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
[TBL] [Abstract][Full Text] [Related]
32. Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma.
Zhang X; Fan W; Hu YY; Li ZM; Xia ZJ; Lin XP; Zhang YR; Liang PY; Li YH
Chin J Cancer; 2015 Jun; 34(6):264-71. PubMed ID: 26063296
[TBL] [Abstract][Full Text] [Related]
33. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
34. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
35. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
[TBL] [Abstract][Full Text] [Related]
36. Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
Capitanio S; Bongioanni F; Piccardo A; Campus C; Gonella R; Tixi L; Naseri M; Pennone M; Altrinetti V; Buschiazzo A; Bossert I; Fiz F; Bruno A; DeCensi A; Sambuceti G; Morbelli S
World J Radiol; 2016 Feb; 8(2):200-9. PubMed ID: 26981229
[TBL] [Abstract][Full Text] [Related]
37. Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT.
Li X; Xie X; Zhang L; Li X; Li L; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Yan J; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Eur J Radiol; 2020 Dec; 133():109301. PubMed ID: 33157372
[TBL] [Abstract][Full Text] [Related]
38. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of sentinel lymph node scintigraphy and 2-[
Reyneke F; Snyman LC; Lawal I; Lengana T; Vorster M; Sathekge M
World J Nucl Med; 2020; 19(3):240-245. PubMed ID: 33354179
[TBL] [Abstract][Full Text] [Related]
40. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.
Hutchings M
Cancer J; 2018; 24(5):215-222. PubMed ID: 30247256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
